Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | CTSD | P07339 | 7/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.43 |
| ▸ | CTSE | P14091 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196431 | 1.00 | BACE1 (1.00) | BACE1CTSDBACE2CTSE | |
| SCHEMBL25916091 | 1.00 | BACE1 (1.00) | BACE1CTSDBACE2CTSE | |
| SCHEMBL3194678 | 0.96 | BACE1 (0.92) | BACE1CTSDBACE2CTSE | |
| SCHEMBL3197231 | 0.92 | BACE1 (0.86) | BACE1CTSDBACE2CTSE | |
| SCHEMBL3185008 | 0.90 | BACE1 (0.82) | BACE1CTSDBACE2CTSE | |
| SCHEMBL3187910 | 0.89 | BACE1 (0.80) | BACE1CTSDBACE2CTSE | |
| SCHEMBL3192386 | 0.89 | BACE1 (0.80) | BACE1CTSDBACE2CTSE | |
| SCHEMBL3193104 | 0.89 | BACE1 (0.80) | BACE1CTSDBACE2 | |
| SCHEMBL3191397 | 0.88 | BACE1 (0.79) | BACE1CTSDBACE2 | |
| SCHEMBL2351687 | 0.86 | BACE1 (0.76) | BACE1CTSDBACE2CTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | NOVARTIS AG | 2010-01-28 | — | — | US | disclosed |
| US-7612055-B2 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | RPS11, MRPL21, RPS4Y1 | BACE1 406/4885CTSD 789/4885BACE2 1071/4885 |
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | RPS11, MRPL21, RPS4Y1 | BACE1 406/4885CTSD 789/4885BACE2 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.